Inhibition of EGFR Overcomes Acquired Lenvatinib Resistance Driven by STAT3-ABCB1 Signaling in Hepatocellular Carcinoma.

Beiyuan Hu Tiantian Zou Wei Qin Xiaotian Shen Yinghan Su Jian-Hua Li Yang Chen Ze Zhang Haoting Sun Yan Zheng Chao-Qun Wang Zhengxin Wang Tian-En Li Shun Wang Le Zhu Xufeng Wang Yan Fu Xudong Ren Qiong-Zhu Dong Lun-Xiu Qin

Published in: Cancer research (2022)

HCC cells acquire resistance to lenvatinib by activating the EGFR-STAT3-ABCB1 pathway, identifying combined treatment with erlotinib as a strategy to overcome acquired resistance and improve the clinical benefit of lenvatinib.

Keyphrases

epidermal growth factor receptor
small cell lung cancer
tyrosine kinase
induced apoptosis
cell proliferation
signaling pathway
cell cycle arrest
combination therapy